Cargando…

Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Humaidan, P., Chin, W., Rogoff, D., D'Hooghe, T., Longobardi, S., Hubbard, J., Schertz, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946864/ https://www.ncbi.nlm.nih.gov/pubmed/28541398 http://dx.doi.org/10.1093/humrep/dex208

Ejemplares similares

Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders
por: Humaidan, P., et al.
Publicado: (2017)

Safety of Follitropin Alfa/Lutropin Alfa for Stimulation of Follicular Development
por: Abramova, Nadezda, et al.
Publicado: (2018)

Recombinant follitropin alfa/lutropin alfa in fertility treatment
por: Gibreel, Ahmed, et al.
Publicado: (2010)

Assessment of the biopotency of follitropin alfa and lutropin alfa combined in one injection: a comparative trial in Sprague-Dawley rats
por: Alper, Michael, et al.
Publicado: (2008)

Administration of follitropin alfa and lutropin alfa combined in a single injection: a feasibility assessment
por: Agostinetto, Rita
Publicado: (2009)

The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review
por: Velthuis, Erica, et al.
Publicado: (2020)

Correction to: The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review
por: Velthuis, Erica, et al.
Publicado: (2021)

A 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice: a large, multicentre, observational study
por: Bühler, Klaus, et al.
Publicado: (2011)

Comparative Assessment of the Structural Features of Originator Recombinant Human Follitropin Alfa Versus Recombinant Human Follitropin Alfa Biosimilar Preparations Approved in Non-European Regions
por: Manzi, Lucio, et al.
Publicado: (2022)

A large, multicentre, observational, post-marketing surveillance study of the 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice for assisted reproductive technology
por: Bühler, Klaus, et al.
Publicado: (2014)

Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis
por: Chua, Su Jen, et al.
Publicado: (2021)

Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study
por: Patel, Nayana Hitesh, et al.
Publicado: (2023)

A comparison of menotropin, highly-purified menotropin and follitropin alfa in cycles of intracytoplasmic sperm injection
por: Esteves, Sandro C, et al.
Publicado: (2009)

Erratum: Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study
Publicado: (2023)

The Effect of Follitropin Alfa in Controlled Ovarian Stimulation Protocol for In Vitro Fertilization Cycles
por: Prasetiawati, Novita, et al.
Publicado: (2023)

Correction: Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis
por: Venetis, Christos A., et al.
Publicado: (2023)

Glycosylation Pattern and in vitro Bioactivity of Reference Follitropin alfa and Biosimilars
por: Riccetti, Laura, et al.
Publicado: (2019)

Correction to: Case series of sebelipase alfa hypersensitivity reactions and successful sebelipase alfa rapid desensitization.
Publicado: (2020)

Managing infertility with the follitropin alfa prefilled pen injector – patient considerations
por: Bühler, Klaus
Publicado: (2015)

In vitro fertilization cycles stimulated with follitropin delta result in similar embryo development and quality when compared with cycles stimulated with follitropin alfa or follitropin beta
por: Haakman, Olga, et al.
Publicado: (2020)

Effectiveness of corifollitropin alfa used for ovarian stimulation of poor responder patients
por: Selman, Helmy, et al.
Publicado: (2016)

Ovulation induction with minimal dose of follitropin alfa: a case series study
por: Bruna-Catalán, Isidoro, et al.
Publicado: (2011)

Comparing a biosimilar follitropin alfa (Cinnal-fⓇ) with Gonal-fⓇ in women undergoing ovarian stimulation: An RCT
por: Hossein Rashidi, Batool, et al.
Publicado: (2021)

Human factors engineering and design validation for the redesigned follitropin alfa pen injection device
por: Mahony, Mary C, et al.
Publicado: (2015)

A cost-effectiveness evaluation comparing originator follitropin alfa to the biosimilar for the treatment of infertility
por: Gizzo, Salvatore, et al.
Publicado: (2016)

A redesigned follitropin alfa pen injector for infertility: results of a market research study
por: Abbotts, Carole, et al.
Publicado: (2011)

Clinical Efficacy of Follitropin Alfa in GnRH-Antagonist Protocols: A Prospective Observational Phase IV Study on the Use of Biosimilar Follitropin Alfa r-hFSH in Assisted Reproductive Technology in a Routine Care Setting
por: Griesinger, Georg, et al.
Publicado: (2021)

Corifollitropin alfa for poor responders patients, a prospective randomized study
por: Fusi, F. M., et al.
Publicado: (2020)

Comparative effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG HP) in assisted reproductive technology (ART) treatments: a non-interventional study in Germany
por: Bühler, Klaus F., et al.
Publicado: (2021)

Patient evaluation of the use of follitropin alfa in a prefilled ready-to-use injection pen in assisted reproductive technology: an observational study
por: Welcker, J Thomas, et al.
Publicado: (2010)

ALFA
por: Hiller, Karlheinz
Publicado: (2012)

Profile of follitropin alpha/lutropin alpha combination for the stimulation of follicular development in women with severe luteinizing hormone and follicle-stimulating hormone deficiency
por: Rinaldi, Leonardo, et al.
Publicado: (2016)

Corifollitropin alfa versus follitropin beta: an economic analysis alongside a randomized controlled trial in women undergoing IVF/ICSI
por: Khoa, Le Dang, et al.
Publicado: (2020)

Efficacy and Safety of Pergoveris in Assisted Reproductive Technology—ESPART: rationale and design of a randomised controlled trial in poor ovarian responders undergoing IVF/ICSI treatment
por: Humaidan, P, et al.
Publicado: (2015)

Corifollitropin Alfa for Controlled Ovarian Stimulation in Assisted Reproductive Technologies: State of the Art
por: Carvalho, Bruno Ramalho de
Publicado: (2023)

CORRIGENDUM: Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)
Publicado: (2012)

Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study
por: Kaplan, Sigal, et al.
Publicado: (2021)

Phase III trial comparing the efficacy and safety of recombinant‐ or urine‐derived human chorionic gonadotropin for ovulation triggering in Japanese women diagnosed with anovulation or oligo‐ovulation and undergoing ovulation induction with follitropin‐alfa
por: Ikenaga, Hideyuki, et al.
Publicado: (2016)

ALFA - Absolute Luminosity measurement For Atlas alias ALFA in ATLAS
por: Sykora, Tomas
Publicado: (2008)

Fine-tuning the dose of recombinant human follicle-stimulating hormone alfa to individualize treatment in ovulation induction and ovarian stimulation cycles: a real-world database analysis
por: Martini, Anne E., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v0ucd90osvf230cea2gftq114q